Nutrition 21 settles IP suit over chromium picolinate

Nutrition 21 settles IP suit over chromium picolinate

Pfizer has acknowledged the validity of Nutrition 21’s asserted patents, allowing the company to continue using chromium picolinate in its Centrum products.

JDS Therapeutics LLC and Nutrition 21 LLC announced that they have entered into a confidential settlement and license agreement with Pfizer Inc., Wyeth LLC and Wyeth Consumer Healthcare LLC (Pfizer).

The settlement ends a patent infringement lawsuit brought by Nutrition 21 against Pfizer in the Southern District of New York related to Pfizer’s use of chromium picolinate in its Centrum® brand line of products. The financial terms of the settlement are confidential. However, in conjunction with the settlement, Pfizer has agreed to license Nutrition 21’s patents. In addition, Pfizer has acknowledged the validity of Nutrition 21’s asserted patents. As a result, Pfizer’s Centrum brand line of products may continue to use chromium picolinate.

Michael Satow, president and chief executive officer of Nutrition 21, stated that, “We are delighted that we were able to reach an amicable resolution to our dispute with Pfizer. This reaffirms the strength of Nutrition 21’s patent portfolio which covers compositions and uses of a number of our products, including our Chromax® chromium picolinate.”

Nutrition 21 is represented by Stroock & Stroock & Lavan LLP. Pfizer is represented by Ropes & Gray LLP. 

 

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish